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Review
In 1996, the U.S. Environmental Protection 
Agency (U.S. EPA) Office of Water requested 
the National Research Council (NRC) to 
independently review the available scientific 
database for the health effects of arsenic in 
drinking water and to evaluate the validity 
of the 1988 assessment. The result was the 
NRC report Arsenic in Drinking Water (NRC 
1999). The report analyzed bladder cancer 
risks from arsenic ingestion using mortality 
data from a southwest Taiwanese population 
(Chen et al. 1992; Wu et al. 1989).
In January 2001, using the newly avail-
able data, the U.S. EPA issued a maximum 
contaminant level (MCL) of 10 µg/L for 
arsenic (U.S. EPA 2001a). The 23 January 
2006 compliance date for the arsenic stan-
dard gave the U.S. EPA time to reassess the 
scientific and cost issues and to seek further 
public input on the arsenic regulation (U.S. 
EPA 2001b). As part of this re-evaluation, 
the NRC was requested to update its 1999 
report. The resulting report, Arsenic in 
Drinking Water—2001 Update (NRC 2001), 
concluded that there was a sound database on 
the carcinogenic effects of arsenic in humans 
that was adequate for the purpose of risk 
assessment, and that lung and bladder can-
cer should continue to be the focus of arse-
nic risk assessment for regulatory decision 
making. The NRC report also concluded that 
the human data from southwestern Taiwan 
(Chen et al. 1988a, 1992; Wu et al. 1989) 
used by the U.S. EPA (2001a) in its risk 
assessment remained the most appropriate 
data to determine lifetime cancer risk esti-
mates. Table 1 contains the NRC estimates of 
excess lifetime lung and bladder cancer risks.
The purpose of this review is to evaluate 
whether the recent literature on arsenic and 
lung and bladder cancer is consistent with or 
contradicts the NRC (2001) with respect to 
cancer risk at low (≤ 100 µg arsenic/L) con-
centrations of arsenic in drinking water. We 
searched PubMed for all epidemiology studies 
on arsenic in drinking water and lung and 
bladder cancer published from 2001 through 
September 2010. The following search terms 
were included: arsenic, water, cancer, lung or 
bladder, and epidemiology. As of September 
2010, 195 studies and articles were identified 
in a PubMed search. Studies considered in 
this review specifically assessed lung and blad-
der cancer outcomes and exposure to low lev-
els (≤ 100 µg/L) of arsenic in drinking water. 
Studies not assessing lung and bladder cancer 
from low-arsenic exposure and studies not 
specific to exposure from drinking water were 
excluded. Fourteen epidemiologic studies that 
examined the risk of lung and bladder cancer 
from low arsenic concentrations (≤ 100 µg/L) 
in drinking water were identified (Baastrup 
et al. 2008; Bates et al. 2004; Chen et al. 
2004, 2010a, 2010b; Han et al. 2009; Heck 
et al. 2009; Karagas et al. 2004; Lamm et al. 
2004; Meliker et al. 2007, 2010; Michaud 
et al. 2004; Mostafa et al. 2008; Steinmaus 
et al. 2003).
Ability of an Epidemiology 
Study to Detect the Excess 
Risks Estimated by the NRC
The lung and bladder cancer risks estimated 
by the NRC (2001) were based on an eco-
logical study of a population in an arsenic-
endemic area of southwest Taiwan. The study 
was unique in many aspects. Exposure began 
early in the 20th century, and the population 
was extremely stable (Wu et al. 1989). Chen 
et al. (1992) commented that the affected 
population lived in a confined area and shared 
similar socioeconomic status, living environ-
ments, lifestyles, dietary patterns, and even 
medical facilities; the only major difference 
in environmental exposures in the popula-
tion appeared to be the differences in arsenic 
concentrations in drinking water. Assuming 
that the effect of arsenic is additive to the 
background risk, risks of arsenic-induced lung 
and, in particular, bladder cancer would be 
easier to detect in Taiwan than in the United 
States because of lower background risks in 
Taiwan. The age-adjusted bladder cancer inci-
dence is four times lower in southeastern Asia 
than in North America; the age-adjusted lung 
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Ob j e c t i v e: The purpose of this review is to evaluate the impact of recent epidemiologic literature 
on the National Research Council (NRC) assessment of the lung and bladder cancer risks from 
ingesting low concentrations (< 100 µg/L) of arsenic-contaminated water.
Da t a s O u r c e s, e x t r a c t i O n, a n D synthesis: PubMed was searched for epidemiologic studies 
pertinent to the lung and bladder cancer risk estimates from low-dose arsenic exposure. Articles 
published from 2001, the date of the NRC assessment, through September 2010 were included. 
Fourteen epidemiologic studies on lung and bladder cancer risk were identified as potentially useful 
for the analysis.
cO n c l u s i O n s: Recent epidemiologic studies that have investigated the risk of lung and bladder 
cancer from low arsenic exposure are limited in their ability to detect the NRC estimates of excess 
risk because of sample size and less than lifetime exposure. Although the ecologic nature of the 
Taiwanese studies on which the NRC estimates are based present certain limitations, the data from 
these studies have particular strengths in that they describe lung and bladder cancer risks resulting 
from lifetime exposure in a large population and remain the best data on which to conduct quan-
titative risk assessment. Continued follow-up of a population in northeastern Taiwan, however, 
offers the best opportunity to improve the cancer risk assessment for arsenic in drinking water. 
Future studies of arsenic < 100 µg/L in drinking water and lung and bladder cancer should consider 
adequacy of the sample size, the synergistic relationship of arsenic and smoking, duration of arsenic 
exposure, age when exposure began and ended, and histologic subtype.
Key w O r D s : arsenic, bladder, cancer, dose response, drinking water, lung, risk assessment. Environ 
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cancer incidence is about 40% lower among 
males and about three times lower in females 
in southeastern Asia than in North America 
[International Agency for Research on Cancer 
(IARC) 2008].
Although many strengths existed for 
quantitative risk assessment, the study had 
some limitation given its ecologic design. The 
concentrations of arsenic in drinking water 
for those in the study were based on the 
median value for the wells in the village. The 
NRC recognized that use of the median value 
presented some uncertainty, but a sensitivity 
analysis suggested that use of the median value 
would present little effect on the risk estimate 
(NRC 2001). The NRC further commented 
that the use of an external comparison popu-
lation minimized the effect of exposure mis-
classification on the risk assessment.
Arsenic exposure in the southwest Taiwan 
population was reported to have begun from 
about 1900 to 1910 (Tseng et al. 1968). The 
arsenic exposure therefore could be considered 
to be lifelong in the population that was the 
basis of the NRC cancer risk estimates. This 
is a particularly important consideration if the 
latency period from exposure to development 
of disease is long or if arsenic has different 
effects at different life stages. Although data 
on arsenic concentrations do not exist for each 
year that the population was exposed, Chen 
et al. (1988b) indicate that arsenic concentra-
tions in the wells in the endemic area were sta-
ble over approximately a 13-year period, and it 
is reasonable to assume that the concentrations 
were stable over a longer period of time.
For several reasons, it would be difficult 
for epidemiologic studies to detect the NRC-
estimated cancer risks in the United States. 
First, the excess lung and bladder cancer life-
time risks for low arsenic exposures are small 
compared with the background lifetime risks 
for these diseases. At 10 µg arsenic/L, the cur-
rent U.S. EPA MCL for arsenic in drinking 
water (U.S. EPA 2001c), the excess risk for 
lung cancer would be 30- to 50-fold lower 
than the lifetime risk of lung cancer in the 
United States. The excess risk for bladder 
cancer would be approximately 8- to 14-fold 
lower than the lifetime risk of bladder cancer 
in the United States. The sex-specific lung and 
bladder cancer excess and relative risks (RRs) 
from lifetime exposure to 10 µg arsenic/L are 
compared in Table 2. The excess risk is the risk 
derived by the NRC for 10 µg arsenic/L; the 
RR is the excess risk plus the background risk 
in the United States [National Cancer Institute 
(NCI) 2010] divided by the background risk. 
The highest RR estimated from arsenic in 
drinking water is for bladder cancer among 
females, largely because the background risk of 
bladder cancer among U.S. females (0.0094) is 
lower than the background risk for lung cancer 
among females and the background risks of 
lung and bladder cancer among males. Age-
standardized risks for male and female lung and 
bladder cancer follow a similar pattern world-
wide (IARC 2007). Evidence that the RRs 
from arsenic exposure in the drinking water 
are highest for bladder cancer among females 
is supported by studies in Chile (Marshall et al. 
2007) and Taiwan (Chen et al. 1985).
Second, the study population on which 
the NRC estimates are based is determined to 
have lifetime or near-lifetime exposure. Finding 
other populations with lifetime exposure would 
be difficult. Besides the shorter exposure dura-
tion experienced by those with less than lifetime 
exposure, exposures at some life stages (e.g., 
infant vs. adult) could present more risk than 
at other life stages (Halmes et al. 2000; Smith 
et al. 2006; Waalkes et al. 2003). Both of these 
exposure issues would diminish the ability of a 
study to detect the risks estimated by NRC.
Finally, dietary arsenic would play a much 
greater role in misclassification of exposure at 
low doses than it would at high doses (Cantor 
and Lubin 2007; Kile et al. 2007; Uchino 
et al. 2006). As the NRC noted, the detec-
tion of the theoretical risks that they estimated 
would require a large population consuming 
drinking water containing arsenic over an 
extended period of time.
In Table 3, we demonstrate the sample 
sizes needed to detect the bladder cancer risk 
from lifetime arsenic exposure in females based 
on the NRC estimates and a background 
lifetime bladder cancer risk among females 
in the United States from the Surveillance 
Epidemiology End Results (SEER) data (NCI 
2010), assuming 80% statistical power and a 
type 1 error (false-positive rate) of p = 0.05. 
Sample sizes were estimated using STATA 
10 (StataCorp LP, College Station, TX). The 
sample size needed to detect an excess blad-
der cancer risk in females is smaller than the 
sample size needed to detect a lung cancer 
risk in females or a lung or bladder cancer 
risk in males, as the RR for bladder cancer in 
females is greater (Table 2). Less than lifetime 
exposure and exposure misclassification will 
increase the sample sizes described in Table 3. 
Furthermore, if lung and bladder cancer risks 
exist at low doses, they could be overestimated 
by the NRC’s linear model of high-dose expo-
sure. Thus, for several reasons, the sample sizes 
described in Table 3 are conservative, and the 
sample sizes required to detect arsenic-induced 
cancer risks could actually be much greater. 
The approach used for the sample size calcula-
tions presented in Table 3 is also applicable to 
unmatched case–control studies. It should be 
clear that sample size calculations are essentially 
approximate, and it is not practical to present 
more precise calculations under all conceivable 
conditions (e.g., matched vs. unmatched, dis-
crete vs. continuous variables). Even under the 
same condition such as discrete (or categorized) 
variable, the sample size can depend on the 
number of categories involved. For instance, 
Mehta and Hilton (1993) have demonstrated 
that sample sizes calculated under conditional 
and nonconditional distributions could dif-
fer significantly, depending on the number of 
cate  gories for the target variable involved.
Epidemiology Studies 
Conducted Since the 
NRC Report
The epidemiologic studies that have examined 
the risk of lung and bladder cancer published 
since NRC (2001) include four cohort studies   
(Baastrup et al. 2008; Chen et al. 2004, 2010a, 
2010b), seven case–control studies (Bates 
et al. 2004; Heck et al. 2009; Karagas et al. 
2004; Meliker et al. 2010; Michaud et al. 
2004; Mostafa et al. 2008; Steinmaus et al. 
Table 1. NRC (2001)a estimates of lifetime can-
cer risks per 10,000 people in relation to arsenic 
  concentration.
Cancer risk
Concentration 
(µg arsenic/L)
Lung Bladder
Females Males Females Males
3 5 4 4 7
5 9 7 6 11
10 18 14 12 23
20 36 27 24 45
aReprinted with permission the National Academies 
Press (2001).
Table 2. Excess lifetime risks, background life-
time risks, and relative lifetime risks for bladder 
and lung cancer from a lifetime consumption of   
10 µg arsenic/L, by sex.
Type of 
cancer
NRC-excess  
lifetime riska
Background- 
lifetime riskb 
NRC-relative  
lifetime riskc
Bladder
Males 0.0023 0.0315 1.07
Females 0.0012 0.0094 1.13
Lung
Males 0.0014 0.0689 1.02
Females 0.0018 0.0554 1.03
Lifetime risk is through age 85 years. 
aData from NRC (2001). bData from SEER (2006a, 2006b). 
cRelative lifetime risk = (excess lifetime risk + back-
ground lifetime risk) ÷ background lifetime risk.
Table 3. Sample sizes required for 80% statistical 
power and type 1 error = 0.05 to detect bladder 
cancer in a cohort study of females for a range of 
arsenic concentrations.
Arsenic (µg/L) Excess riska RRb
Sample size 
(80% power)
100 0.012 2.28 672
50 0.006 1.64 2,381
20 0.0024 1.26 13,613
10c  0.0012 1.13 52,640
3 0.0004 1.04 462,527
aEstimates from NRC (2001). bBackground [(excess life-
time risk + background lifetime risk) ÷ background life-
time risk. The lifetime risk for women up to age 85 years 
for bladder cancer, years 2004–2006, is 0.0094 (0.94%) 
(NCI 2010). cCurrent U.S. EPA MCL for arsenic is 10 µg/L 
(U.S. EPA 2001c).Gibb et al.
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2003), and three ecologic studies (Han et al. 
2009; Lamm et al. 2004; Meliker et al. 2007). 
Seven studies examined bladder cancer risk 
(Bates et al. 2004; Chen et al. 2010b; Karagas 
et al. 2004; Lamm et al. 2004; Meliker et al. 
2010; Michaud et al. 2004, Steinmaus et al. 
2003), four examined lung cancer risk (Chen 
et al. 2004, 2010a, Heck et al. 2009; Mostafa 
et al. 2008), and three examined both lung 
and bladder cancer risk (Baastrup et al. 2008; 
Han et al. 2009; Meliker et al. 2007). Of these 
14 studies, 11 used arsenic concentration in 
drinking water as the measure of arsenic expo-
sure (Baastrup et al. 2008; Bates et al. 2004; 
Chen et al. 2004, 2010a, 2010b; Han et al. 
2009; Heck et al. 2009; Lamm et al. 2004; 
Meliker et al. 2007, 2010; Mostafa et al. 2008; 
Steinmaus et al. 2003). Three studies (Heck 
et al. 2009; Karagas et al. 2004; Michaud et al. 
2004) examined toenail arsenic as a surrogate 
measure of exposure. Toenail arsenic is believed 
to represent primarily ingested arsenic. Table 4 
briefly describes the 14 epidemiologic studies 
and indicates whether there is any evidence of 
Table 4. Studies published since 2001 that examined the risk of lung, urinary, and bladder cancer for arsenic concentrations in drinking water < 100 µg/L.
Authors Study size Location Cancer type Measures of association (95% CI)
Cohort studies
Baastrup et al. 2008 56,378 Denmark Bladder 0.7 µg/L [IRR = 1.01 (0.93–1.11)]
Lung 0.7 µg/L [IRR = 0.99 (0.92–1.07)]
Chen et al. 2004 2,503 Southwest Taiwan Lung < 10 µg/L; RR = 1.0
8,088 Northeast Taiwan 10–99 µg/L [RR = 1.09 (0.63–1.91)]
100–299 µg/L [RR = 2.28 (1.22–4.27)]
300–699 µg/L [RR = 3.03 (1.62–5.69)]
≥ 700 µg/L [RR = 3.29 (1.60–6.78)]
p-trend < 0.001
Chen et al. 2010a 8,086 Northeast Taiwan Lung < 10 µg/L; RR = 1.0
10–49.9 µg/L [RR = 1.10 (0.74–1.63)]
50–99.9 µg/L [RR = 0.99 (0.59–1.68)]
100–299 µg/L [RR = 1.54 (0.97–2.46)]
≥ 300 µg/L [RR = 2.25 (1.43–3.55)]
p-trend = 0.001
Chen et al. 2010b 8,086 Northeast Taiwan Urinary < 10 µg/L; RR = 1.0
10–49.9 µg/L [RR = 1.66 (0.53–5.21)]
50–99.9 µg/L [RR = 2.42 (0.69–8.54)]
100–299 µg/L [RR = 4.13 (1.32–12.9)]
≥ 300 µg/L [RR = 7.80 (2.64–23.1)]
p-trend < 0.001
Case–control studies
Bates et al. 2004 114 cases
114 controls
Argentina Bladder For arsenic exposure 1–10 years before interview including proxy well 
measurements:
0–10 µg/L; OR = 1.00
> 10 µg/L [OR = 0.75 (0.4–1.7)]
Heck et al. 2009 223 cases
283 controls
New Hampshire and 
Vermont, USA
Lung NA—exposure measured by toenail arsenic
Karagas et al. 2004 383 cases
641 controls
New Hampshire, USA Bladder NA—exposure measured by toenail arsenic
Meliker et al. 2010 411 cases
566 controls
Southeastern 
Michigan, USA
Bladder < 1 µg/L; OR = 1.00
1–10 µg/L [OR = 0.84 (0.63–1.12)]
> 10 µg/L [OR = 1.10 (0.65–1.86)]
Michaud et al. 2004 280 cases
293 controls
Southwest Finland Bladder NA—exposure measured by toenail arsenic
Mostafa et al. 2008 2,811 cases
1,183 controls
Bangladesh Lung Smokers
≤ 10 µg/L; OR = 1.0
11 ≤ 50 µg/L [OR = 1.25 (0.96–1.62)]
51 ≤ 100 µg/L [OR = 1.37 (0.92–2.03)]
101–400 µg/L [OR = 1.65 (1.25–2.18)]
Nonsmokers
≤ 10 µg/L; OR = 1.0
11 ≤ 50 µg/L [OR = 0.90 (0.62–1.33)]
51 ≤ 100µg/L [OR = 1.10 (0.62–1.96)]
101–400 µg/L [OR = 0.94 (0.62–1.41)]
Steinmaus et al. 2003 181 cases
328 controls
California and 
Nevada, USA
Bladder For arsenic exposures with a 40-year lag and highest 20-year average:
< 10 µg arsenic/day; OR = 1.0
10–80 µg arsenic/day [OR = 1.28 (0.53–3.11)]
> 80 µg arsenic/day [OR = 1.70 (0.73–3.96)]
Ecologic studies
Han et al. 2009 44 counties Idaho, USA Bladder Pearson correlation coefficient of arsenic in ground water and bladder 
cancer incidence = 0.02 (p = 0.9)
Lung Pearson correlation coefficient of arsenic in ground water and lung 
cancer incidence = 0.25 (p = 0.1)
Lamm et al. 2004 133 counties USA Bladder 3–60 µg/L (82%; 3–5 µg/L):
Regression analysis found no association of bladder cancer mortality 
with arsenic in drinking water
Meliker et al. 2007 6 counties Southeastern 
Michigan, USA
Bladder 7.58 µg/L (population-weighted median) [SMR = 0.94 (0.82–1.08)]
Lung 7.58 µg/L (population-weighted median) [SMR = 1.02 (0.98–1.06)]
Abbreviations: NA, not applicable; SMR, standardized mortality ratio.Recent studies on arsenic and lung/bladder cancer
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significantly (p < 0.05) increased lung or blad-
der cancer risks associated with drinking water 
concentrations < 100 µg arsenic/L. Brief sum-
maries of each study are provided below.
Cohort studies. Baastrup et al. (2008) 
reported on 56,378 Danish men and women, 
50–64 years of age at enrollment between 
1993 and 1997, who were followed until date 
of first cancer diagnosis, emigration, death, 
or 1 August 2003. Time-weighted average 
exposure and cumulative exposure to arse-
nic were based on residential history between 
1970 and 2003. Arsenic concentrations for 
utilities (i.e., drinking water treatment sys-
tems) were based on data for 1987 through 
2004, with most measurements taken between 
2002 and 2004. The average at each water 
utility was assumed to represent the arsenic 
concentrations throughout the study period of 
1970–2003. Questionnaires administered to 
study participants assessed potential lifestyle, 
occupational, and environmental risks. During 
the follow-up period, 214 bladder cancer cases 
and 402 lung cancer cases were diagnosed. The 
time-weighted arsenic exposure of the cohort 
members ranged from 0.05 to 25.3 µg/L, 
with a median and mean concentration of 0.7 
µg/L and 1.2 µg/L, respectively. Incidence rate 
ratios (IRRs), adjusted for a variety of different 
variables, found no association between the 
time-weighted average or cumulative expo-
sures and lung or bladder cancer. Relative risks 
were not reported by sex.
In an earlier study, Chen et al. (2004) 
described 2,503 residents of southwest 
Taiwan and 8,088 residents of northeast 
Taiwan followed for an average period of 
8 years. All those in the cohort had consumed 
arsenic-contaminated water for > 50 years. 
Those in the cohort from southwest Taiwan 
included a group of patients with blackfoot 
disease who were age, sex, and residentially 
matched with healthy community controls. 
Each study participant was administered a 
structured questionnaire to obtain socio-
demographic, residential, and occupational 
history, well water–intake history, and ciga-
rette and alcohol consumption information. 
Average arsenic concentration in drinking 
water was used as the exposure metric. RRs 
and 95% confidence intervals (CIs) were esti-
mated by Cox proportional hazards mod-
els. Adjustment variables in the final model 
included age, sex, years of schooling, study 
cohort (blackfoot disease and matched con-
trols; residents of the arsenic-endemic areas 
in southwest and northeast Taiwan), smoking 
status, and habitual alcohol consumption. 
The researchers identified 139 new, pathologi-
cally confirmed lung cancer cases. When com-
pared with the referent group of < 10 µg/L, 
the adjusted RRs (95% CIs) for lung cancers 
were 1.09 (0.63–1.91); 2.28 (1.22–4.27); 
3.03 (1.62–5.69); and 3.29 (1.60–6.78) for 
average arsenic concentrations of 10–99, 
100–299, 300–699, and ≥ 700 µg/L, respec-
tively. The trend was statistically significant. A 
strong synergism was found between arsenic 
in water and cigarette consumption. For those 
smoking ≥ 25 pack-years, RRs (95% CIs) 
for lung cancer were 3.8 (1.29–11.2), 5.93 
(2.19–16.1), and 11.10 (3.32–37.2) for aver-
age arsenic concentrations of < 10, 10–699, 
and ≥ 700 µg/L, respectively.
In the Taiwan cohort, Chen et al. (2010a, 
2010b) studied 8,086 northeastern Taiwanese 
residents. Drinking water concentration was 
reported at time of enrollment. A total of 3,901 
well-water samples were collected from 4,584 
(85.1%) households during the home inter-
view. No information on the arsenic concen-
tration of the well water at prior residences was 
obtained. Detailed residential history and cor-
responding well-water arsenic concentrations 
were used to calculate cumulative exposure 
as well as starting and ending age of exposure 
and duration of exposure. Chen et al. (2010a) 
studied various exposure metrics such as the 
effect of age when drinking water containing 
arsenic was started and stopped, years of drink-
ing well water, and cumulative exposure in 
estimating lung cancer risk. RRs were adjusted 
for age, sex, education, cigarette-smoking 
status, and alcohol consumption at enroll-
ment. The RRs and 95% CIs for 100–300   
and > 300 µg arsenic/L when compared with 
< 10 µg arsenic/L were 1.54 (0.97–2.46) and 
2.25 (1.43–3.55), respectively. There was 
no apparent increased risk at concentrations 
between 10 and 100 µg arsenic/L, but when 
duration of exposure was accounted for, all 
levels of exposure including low concentra-
tions were in the direction of an increased risk 
of lung cancer. These associations tended to 
increase with longer durations of exposure. 
A synergistic effect of arsenic exposure and 
cigarette smoking was found for squamous- 
and small-cell carcinomas, but not for adeno-
carcinoma. Chen et al. (2010b) identified 45 
incident cases of urinary cancer. Data showed 
a significant (p < 0.001) monotonic increasing 
risk of urinary cancer with arsenic concentra-
tion. Compared with those consuming < 10 µg 
arsenic/L, the age and sex-adjusted RRs 
(95% CIs) for 10–49.9, 50–99.9, 100–299.9, 
and ≥ 300 µg arsenic/L were 1.7 (0.56–5.19), 
2.49 (0.73–8.59), 4.18 (1.3–12.8), and 7.73 
(2.69–22.3), respectively. The trend was highly 
significant (p < 0.001). Urinary cancer RRs 
(95% CIs) for cumulative arsenic exposures 
400–1,000, 1,000–5,000, 5,000–10,000, and 
≥ 10,000 µg/L-year were 1.16 (0.29–4.64), 
2.44 (0.91–6.5), 3.88 (1.18–12.7), and 7.55 
(2.79–20.4), respectively, compared with < 400 
µg/L-year. There was a monotonic increase in 
risk with cumulative exposure. The association 
with arsenic was strongest for urothelial cancer 
(transitional-cell carcinoma).
Case–control studies. Bates et al. (2004) 
described 114 incident bladder cancer cases in 
Argentina from previously determined high- 
and medium-exposure counties matched on 
age, sex, and county with 114 controls. Cases 
were between the ages of 20 and 80, had lived 
in the high- and medium-exposure counties 
between 1996 and 2000, and were alive at the 
time of the study. Controls were identified 
from voter registration records. The following 
data were collected: residential history, smok-
ing, consumption of fluids, and occupational 
and medical history. Water samples were col-
lected at the current residence and all previous 
residences and analyzed for arsenic. Where 
the well at a former residence was closed, a 
sample was collected from a nearby (proxy) 
well. Exposure was defined by average arsenic 
concentration, time-weighted water arsenic 
consumption, which was adjusted for total 
fluid consumption, and consumption of well 
water during 10-year intervals before the inter-
view. The investigation found no evidence of 
an association between measures of exposure, 
based on arsenic concentration, and bladder 
cancer. Drinking well water for 51 to 70 years 
before the interview was found to be associated 
with an increased risk of bladder cancer among 
ever-smokers [odds ratio (OR) = 2.5; 95% CI, 
1.1–5.5) but not among never smokers.   
Mean, median, and range time-weighted arse-
nic exposure levels, respectively, were 20, 1.3, 
and 0 to 212 µg/L for cases and 45, 1.2, and 
0–997 µg/L for controls, when proxy wells 
were excluded. Risks were not reported by sex.
Heck et al. (2009) studied 223 incident 
lung cancer cases from state cancer registries 
and 283 controls from a commercial database, 
frequency matched by five-year-age group and 
sex, in 10 counties in New Hampshire and 
Vermont. Participants were interviewed in per-
son and were asked to provide biological sam-
ples (blood, toenail clippings, oral buccal cells 
from brushing, and oral cells from a mouth-
wash sample). Arsenic exposure was based on 
toenail clippings. Small-cell and squamous-cell 
carcinoma of the lung (OR = 2.75; 95% CI, 
1.00–7.57) was associated with toenail arsenic 
concentration ≥ 0.114 µg/g versus < 0.05 µg/g. 
The authors also observed an elevated risk of 
lung cancer among participants with a history 
of lung disease and toenail arsenic ≥ 0.05 µg/g 
(OR = 4.78; 95% CI, 1.87–12.2) as compared 
with individuals with low toenail arsenic and 
no history of lung disease.
Karagas et al. (2004) reported 383 cases 
of transitional-cell carcinoma of the bladder 
identified from the New Hampshire Cancer 
Registry and 641 controls from the general 
population. Toenail arsenic was used as the 
measure of exposure. There was an increased 
risk of transitional cell bladder cancer among 
ever-smokers at the highest versus the lowest 
toenail arsenic concentration, but not among Gibb et al.
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all subjects or never-smokers at any concen-
tration. The geometric mean (GM) values 
of toenail arsenic [standard error (SE) of the 
GM] were 0.087 µg/g (SE = 0.003 µg/g) and 
0.090 µg/g (SE = 0.002 µg/g) for cases and 
controls, respectively.
Meliker et al. (2010) studied 411 bladder 
cancer cases and 566 controls in 11 counties 
of southeastern Michigan (USA). Cases diag-
nosed between 2000 and 2004 were ascer-
tained from the Michigan Cancer Surveillance 
program. Controls were frequency-matched to 
cases on age, sex, and race. Study participants 
were required to have lived in the defined 
area for at least 5 years. Water consumption, 
dietary habits, smoking, medical history, and 
residential and occupational history were 
determined by questionnaire. Lifetime arsenic 
exposure was determined based on residen-
tial history. No association between bladder 
cancer and arsenic concentration in drinking 
water was observed. Relative risks were not 
reported by sex.
Mostafa et al. (2008) published a study 
of 2,811 male lung cancer cases and 1,183 
male controls in Bangladesh. The study com-
pared primary lung cancer cases with cases 
with benign lung lesions. Arsenic exposure was 
determined through a sampling of tube wells 
by the British Geological Survey and responses 
to questionnaires on residence and tube well 
use. Among smokers, the relative risks (95% 
CIs), compared with the reference group (< 10 
µg arsenic/L), were 1.25 (0.96–1.62), 1.37 
(0.92–2.03), and 1.65 (1.25–2.18) for con-
centrations 11–50, 51–100, and 101–400 µg 
arsenic/L, respectively. Among nonsmokers, 
the researchers found neither an increasing 
trend in OR nor a statistically significant OR 
at any exposure level.
Michaud et al. (2004) studied 280 blad-
der cancer cases and 293 controls (all male) in 
Southwest Finland. Cases and controls were 
smokers at the time of enrollment into the 
Alpha-Tocopherol, Beta-Carotene Prevention 
Study. ORs were estimated from uncondi-
tional logistic regression models adjusted 
for age, date at toenail collection, trial inter-
vention group (Alpha-Tocopherol or Beta-
Carotene), number of cigarettes per day, and 
number of years of smoking. No relationships 
between toenail arsenic concentrations and 
bladder cancer risk were found. Median toe-
nail arsenic concentrations were 0.110 µg/g 
(range = 0.014–2.62 µg/g) and 0.105 µg/g 
(range = 0.017–17.5 µg/g) for cases and con-
trols, respectively.
Steinmaus et al. (2003) studied 181 pri-
mary bladder cancer cases and 328 controls 
in California and Nevada. Cases diagnosed 
between 1994 and 2000 were identified from 
the Nevada Cancer Registry and the Cancer 
Registry of Central California. Population 
controls were age and sex matched. Arsenic 
measurements for all community-supplied 
drinking water wells were obtained from the 
health departments of the respective states. 
Questionnaires were administered to all 
partici  pants. Arsenic exposures were classi-
fied by the highest 1-year average, highest 
5-year average, highest 20-year average, and 
cumulative exposure. The percentages of cases 
and controls consuming different concentra-
tions of arsenic (0–19, 20–79, 80–120, and 
> 120 µg/L) were similar, with the vast major-
ity consuming 0–19 µg/L. The only significant 
associations were found after a 40-year lag in 
ever-smokers exposed to > 80 µg arsenic/day 
(OR = 3.67; 95% CI, 1.43– 9.42). Relative 
risks were not reported by sex.
Ecologic studies. Han et al. (2009) com-
pared cancer incidence by the arithmetic 
mean arsenic concentrations of ground water 
in 44 counties in Idaho, USA. Arsenic con-
centrations for the counties were based on 
approximately 1,990 groundwater sources 
sampled between 1991 and 2005. Newly 
diagnosed cases of cancer of the bladder, kid-
ney and renal pelvis, liver and bile duct, lung 
and bronchus, and non-Hodgkin lymphoma 
from 1991 to 2005 were identified from the 
Cancer Registry of Idaho. Counties were 
grouped into arsenic water concentrations of 
< 2 µg/L (n = 23), 2 to < 10 µg/L (n = 16), 
and ≥ 10 µg/L (n = 5). Using regression anal-
ysis and controlling for smoking, race, sex, 
body mass index, and population density, the 
researchers found no evidence of an associa-
tion between arsenic and cancer incidence in 
the 44 counties.
Lamm et al. (2004) studied 133 U.S. coun-
ties that depend exclusively on groundwater. 
Bladder cancer standardized mortality ratios 
(SMR) for white males, from 1950 to 1979, 
were plotted against median county arsenic 
concentrations in groundwater. SMRs for 
white males were not related to the median or 
mean county arsenic concentrations. Median 
county arsenic concentrations ranged from 3 to 
60 µg/L. Eighty-two percent of the population 
studied was assumed to have consumed 3–5 µg 
arsenic/L.
Meliker et al. (2007) investigated six 
counties in southeastern Michigan. Deaths for 
the six counties and for the state of Michigan 
from 1979 to 1997 were used to estimate 
the sex-specific SMRs. Data from Michigan 
Department of Environmental Quality from 
1983 through 2002 were used to estimate 
county-level mean and median arsenic con-
centrations for the six counties and for the 
rest of Michigan. The SMRs for lung, bron-
chus, and trachea cancer and for bladder can-
cer were not significantly increased among the 
six counties as a whole. The SMRs for lung, 
trachea, and bronchus cancer were signifi-
cantly increased in both males and females in 
Genesee County, the most populous, urban, 
and racially diverse of the six counties. The six-
county study area had a population-weighted 
mean arsenic concentration of 11.00 µg/L and 
a population-weighted median of 7.58 µg/L. 
The population-weighted mean in the remain-
der of Michigan was 2.98 µg/L with a median 
of 1.27 µg/L.
Discussion
As indicated by Table 4, few studies reported 
significantly increased risks of lung or bladder 
cancer from exposure to < 100 µg arsenic/L. 
That does not suggest, however, that the lung 
and bladder cancer excess risks estimated by 
the NRC are incorrect. The sample sizes, with 
type 1 error = 0.05 and power = 0.80, needed 
to detect the NRC-estimated excess risks of 
bladder cancer in females are relatively large 
(Table 3). The sample sizes needed to detect 
associations with lung cancer in females or 
lung or bladder cancer in males would be even 
larger. None of the studies conducted since the 
NRC report had sample sizes large enough to 
detect the excess risks estimated by the NRC. 
Nevertheless, there is evidence of increased 
lung and bladder cancer risk from exposures 
< 100 µg arsenic/L in the recent studies, par-
ticularly in the studies by Chen et al. (2010a, 
2010b). The monotonic dose response seen 
across all exposures in Chen et al. (2010b) 
and the significant trend (p < 0.001) for dose 
response provides strong evidence for the blad-
der cancer risks seen at the lower exposures.
The three case–control studies that exam-
ined the relative risks of bladder cancer from 
low-arsenic drinking water concentration 
drew cases and controls from arsenic-endemic 
areas (Bates et al. 2004; Meliker et al. 2010; 
Steinmaus et al. 2003). The reason for draw-
ing cases and controls from the same area is, of 
course, to minimize potential differences other 
than the factor under study (i.e., arsenic). 
Drawing cases and controls from the same 
area, however, may also reduce the difference 
in arsenic exposure, requiring a larger sample 
size to determine whether an excess risk exists 
for a given exposure. Exposure misclassifica-
tion probably further reduced the difference 
between groups. Because the estimated expo-
sure difference between cases and controls was 
minimal in each of these studies, the statistical 
power to detect the excess risks predicted by 
the NRC would also have been minimal.
Two of the case–control studies that 
examined bladder cancer (Karagas et al. 2004; 
Michaud et al. 2004) used toenail arsenic 
as the measure of exposure. According to 
Karagas et al. (2000), 1 µg arsenic/L water 
corresponds to 0.1 µg arsenic/g toenail, 
whereas a doubling of toenail arsenic concen-
tration is associated with a 10-fold increase in 
water arsenic in samples with ≥ 1 µg arsenic/L. 
Based on this relationship, cases and controls 
in all three studies would have been exposed Recent studies on arsenic and lung/bladder cancer
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to approximately ≤ 1 µg arsenic/L. Even if 
this level of exposure were assumed to be life-
time, the power of the studies of Karagas et al. 
(383 cases, 641 controls) and Michaud et al. 
(280 cases, 293 controls) to detect the blad-
der cancer relative risk estimated by the NRC 
(2001) would have been minimal. Toenail 
arsenic is considered a reliable indicator of 
arsenic exposure, with the strongest relation-
ship being drinking water–arsenic exposure 
(Adair et al. 2006). When the concentration 
of arsenic in water is low, however, the contri-
bution of arsenic to toenail arsenic concentra-
tions becomes less clear as other sources (e.g., 
food, air, dermal absorption) become more 
important (Slotnick and Nriagu 2006).
Han et al. (2009), Lamm et al. (2004), 
and Meliker et al. (2007) were ecologic stud-
ies. The exposure metric in all three was an 
average exposure measurement by county, 
a much larger geopolitical unit than the vil-
lages in the Taiwan study. Lamm et al. (2004) 
relied on U.S. Geological Survey (USGS) data 
for mean and median arsenic concentrations 
by county (Focazio et al. 1999). The USGS 
data were based on as few as five wells per 
county and were not restricted to wells used 
for drinking water. All three ecologic studies 
were conducted in the United States, where 
the population is very transient—much more 
transient than, for example, the southwest 
Taiwanese population that is the basis of the 
NRC risk estimates. Hansen (1998) reported 
that the median duration in a residence for 
those in the United States is only 5.2 years. 
In addition, the U.S. population consumes 
different sources of fluids (e.g., tap water 
from other jurisdictions, bottled beverages) 
in addition to potentially contaminated well 
water, whereas those in southwest Taiwan 
likely consumed well water as their principal, 
if not the only, source of fluids. Furthermore, 
both Lamm et al. (2004) and Meliker et al. 
(2007) examined bladder cancer mortality 
rather than incidence. The NRC estimates 
are for cancer incidence. Because the 5-year 
survival rate for bladder cancer is approxi-
mately 80% (American Cancer Society 2010), 
studies based on bladder cancer mortal-
ity would underestimate the risks described 
by NRC. Finally, the arsenic exposures in 
all three studies were very low (< 10 µg/L). 
Han et al. (2009) compared incidence of 
cancer for different sites by low (< 2 µg/L), 
medium (2–9 µg/L), and high (≥ 10 µg/L) 
arsenic counties. The median arsenic con-
centrations in the counties studied by Lamm 
et al. (2004) were 3–60 µg/L, with 65% of 
the counties and 82% of the population in 
the range of 3–5 µg/L. The six Michigan 
counties studied by Meliker et al. (2007) had   
population-weighted mean and median arse-
nic concentrations of 11.00 µg/L and 7.58 
µg/L, respectively, compared with 2.98 µg/L 
and 1.27 µg/L for the remainder of the state. 
The differences were relatively small.
Some of the recent studies suggest that 
the ability of an epidemiologic study of arse-
nic exposure to detect associations with lung 
or bladder cancer could be impacted by the 
number of smokers in the study population. 
Bates et al. (2004), Karagas et al. (2004), and 
Steinmaus et al. (2003) all report an increased 
risk of bladder cancer in smokers, but not 
nonsmokers, exposed to relatively low concen-
trations of arsenic in drinking water. The eco-
logic study by Meliker et al. (2007) found a 
significant increase in lung cancer mortality for 
the most urbanized of the six arsenic-endemic 
counties (Genesee County). Because the preva-
lence of smoking in the most urbanized county 
was expected to be higher than in the other 
five counties, the authors suggested the signifi-
cant elevation in lung cancer mortality is due 
to the synergy between arsenic and smoking. 
An earlier study by Kurttio et al. (1999) also 
presents evidence of an interaction between 
smoking and arsenic with respect to bladder 
cancer, while Chen et al. (2004), Ferreccio 
et al. (2000), and Mostafa et al. (2008) sug-
gest an interaction between smoking and arse-
nic with respect to lung cancer. Chen et al. 
(2010a) found a synergistic effect of arsenic 
exposure and cigarette smoking for squamous- 
and small-cell carcinomas of the lung but not 
for adenocarcinoma. The authors also reported 
that a relationship between smoking, arsenic, 
and lung cancer was evident by the signifi-
cantly elevated RRs among exposed smokers 
compared with exposed nonsmokers.
The study by Chen et al. (2010b) found 
that drinking arsenic-contaminated water 
since birth had a higher urinary cancer risk 
than beginning to drink arsenic-contaminated 
water later in life. Smith et al. (2006), in a 
study of lung cancer risk in an arsenic-endemic 
area where drinking water concentrations 
were relatively high, found that early lifetime 
exposure may convey a greater risk for lung   
cancer. Bates et al. (1995, 2004), Marshall 
et al. (2007), and Steinmaus et al. (2003) 
found that the latency for arsenic-induced 
cancer was particularly long, indicating that a 
40- to 50-year follow-up may be required to 
detect an excess risk.
The recent studies by Chen et al. (2010a, 
2010b) are noteworthy for their potential 
to improve the quantitative risk assessment 
for arsenic. The population is relatively large 
(8,086) and includes a large number exposed 
since birth. Arsenic-contaminated drinking 
water concentrations range from < 10 µg/L 
to > 300 µg/L. Individual drinking water 
measurements are available for most in the 
cohort, as opposed to the village measurements 
on which the NRC risk estimates are based. 
Data are also available on age of the individu-
als, sex, education, cigarette smoking, habitual 
alcohol consumption, age when the individu-
als started drinking arsenic-contaminated well 
water, and age when the individual stopped 
drinking arsenic-contaminated well water. 
Additional follow-up of this cohort will pro-
vide a valuable database for future risk assess-
ments. Individual data from the study will be 
needed to do a quantitative risk assessment. 
The Health Effects of Arsenic Longitudinal 
Study (HEALS) of an arsenic-exposed cohort 
of almost 20,000 in Bangladesh (Ahsan et al. 
2006; Chen et al. 2009) may also be of use in 
the future in assessing cancer risk at low arsenic 
exposures. The study has collected individual 
data on smoking, education, socio  economic 
status, skin lesions, arsenic exposure (including 
biomarkers of exposure), and other variables.
Conclusion
The NRC estimated excess lifetime lung and 
bladder cancer risks based on a lifetime of 
exposure to arsenic in drinking water. Since 
2001, several studies have evaluated lung and 
bladder cancer risk in persons consuming low 
concentrations of arsenic in drinking water 
(≤ 100 µg/L). These studies lack either the 
statistical power or the information necessary 
to evaluate the bladder and lung cancer risk 
estimates noted in the NRC report (2001). 
Validating the NRC-estimated risks is prob-
lematic given the sample sizes needed, the 
long latency involved, and the greater need 
to control for confounders at low-arsenic 
drinking water concentrations. Some of the 
recent studies, however, suggest that lung and 
bladder cancer risks are increased at concen-
trations ≤ 100 µg arsenic/L. Future studies 
on arsenic ingestion and lung and bladder 
cancer risk would benefit by considering the 
adequacy of the sample size, the synergistic 
relationship of arsenic and smoking, duration 
of arsenic exposure, age when exposure began 
and ended, and examination by histologi-
cal type. Although the data from southwest 
Taiwan continue to provide the best basis for 
the quantitative risk assessment of lung and 
bladder cancer from ingested arsenic, indi-
vidual data from the continued follow-up of 
the population studied by Chen et al. (2010a, 
2010b) should provide an excellent database 
on which to improve the assessment.
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